gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Solute carrier family 39

LIV-1, SLC39A6, ZIP6
Zinc is an essential cofactor for hundreds of enzymes. It is involved in protein, nucleic acid, carbohydrate, and lipid metabolism, as well as in the control of gene transcription, growth, development, and differentiation. SLC39A6 belongs to a subfamily of proteins that show structural characteristics of zinc transporters (Taylor and Nicholson, 2003 [PubMed 12659941]).[supplied by OMIM, Mar 2008] (from NCBI)
Sponsored links
Top mentioned proteins: CAN, V1a, E-cadherin, HAD, ACID
Papers on LIV-1
miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma.
He et al., Shanghai, China. In Oncotarget, Jan 2016
Solute carrier family 39 member 6 (SLC39A6) was identified as a direct and functional target of miR-192.
Characterization of Zinc Influx Transporters (ZIPs) in Pancreatic β Cells: ROLES IN REGULATING CYTOSOLIC ZINC HOMEOSTASIS AND INSULIN SECRETION.
Wheeler et al., Toronto, Canada. In J Biol Chem, Aug 2015
In this study, we examined the β cell and islet ZIP transcriptome and show consistent high expression of ZIP6 (Slc39a6) and ZIP7 (Slc39a7) genes across human and mouse islets and MIN6 β cells.
Effect of LIV1 on the sensitivity of ovarian cancer cells to trichostatin A.
Wang et al., Beijing, China. In Oncol Rep, Feb 2015
In a previous study, we used a functional gene screen approach to identify the key genes responsible for the tumor-selective action of trichostatin A (TSA), of which LIV1, a novel zinc transporter, was isolated by its marked ability to confer resistance against TSA-induced apoptosis.
SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
Benjamin et al., Bothell, United States. In Mol Cancer Ther, 2014
In this article, we describe a novel antibody-drug conjugate (ADC; SGN-LIV1A), targeting the zinc transporter LIV-1 (SLC39A6) for the treatment of metastatic breast cancer.
SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma.
Li et al., Shihezi, China. In J Transl Med, 2014
Recent large-scale genome-wide association studies in Chinese Han populations have identified an ESCC susceptibility locus within the SLC39A6 gene.
Genome wide identification, phylogeny and expression of zinc transporter genes in common carp.
Xu et al., Beijing, China. In Plos One, 2013
Through examining the copy number of zinc transporter genes across several vertebrate genomes, thirteen zinc transporters in common carp are found to have undergone the gene duplications, including SLC30A1, SLC30A2, SLC30A5, SLC30A7, SLC30A9, SLC30A10, SLC39A1, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7 and SLC39A9.
Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma.
Lin et al., Beijing, China. In Nat Genet, 2013
We identified rs1050631 in SLC39A6 as associated with the survival times of affected individuals, with the hazard ratio for death from ESCC in the combined sample being 1.30 (95% confidence interval (CI) = 1.19-1.43;
Migration behavior of breast cancer cells in the environment of high glucose level and the role of zinc and its transporter.
Takatani-Nakase, In Yakugaku Zasshi, 2012
Moreover, Zn(2+) uptake activity into cellular cytosol and the mRNA expression of zinc transporters, ZIP6 and ZIP10, in the high glucose-exposed cells were shown to be especially higher than in the physiological glucose level.
Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue.
Wittliff et al., In Horm Mol Biol Clin Investig, 2012
Coordinate expression of EVL, NAT1, TBC1D9, SCUBE2, RABEP1, SLC39A6, TCEAL1, FUT8, XBP1, PTP4A2 or GATA3 with either ESR1 or PGR was detected.
Tricking the guard: exploiting plant defense for disease susceptibility.
Wolpert et al., Corvallis, United States. In Science, 2012
in LOV1's absence, victorin inhibits TRX-h5, resulting in compromised defense but not disease by C. victoriae; in LOV1's presence, victorin binding to TRX-h5 activates LOV1 and elicits a resistance-like response that confers disease susceptibility
Zinc and cancer: implications for LIV-1 in breast cancer.
Freake et al., Stony Brook, United States. In Nutrients, 2012
LIV-1 (ZIP6) was first described in 1988 as an estrogen regulated gene with later work suggesting a role for this transporter in cancer growth and metastasis.
Zinc transporter mRNA levels in Alzheimer's disease postmortem brain.
Johnston et al., Ireland. In J Alzheimers Dis, 2011
The results of this study showed evidence for a positive correlation between LIV1 and ZnT6 insuperior temporal, occipital, and frontal gyri in patient with alzheimer disease.
The cation selectivity of the ZIP transporters.
Dempski, Worcester, United States. In Curr Top Membr, 2011
There are a total of 14 members of this family, which can be further divided into four subfamilies based on sequence similarities: ZIPI, ZIPII, gufA and LIV-1.
Family reunion--the ZIP/prion gene family.
Schmitt-Ulms et al., Toronto, Canada. In Prog Neurobiol, 2011
More specifically, sequence alignments, structural threading data and multiple additional pieces of evidence placed a ZIP5/ZIP6/ZIP10-like ancestor gene at the root of the PrP gene family.
LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.
Chung et al., Atlanta, United States. In Plos One, 2010
LIV-1 is involved in prostate cancer progression as an intracellular target of growth factor receptor signaling which promoted EMT and cancer metastasis
Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma.
Kizek et al., Brno, Czech Republic. In Curr Med Chem, 2010
Imbalance of their regulation is described in cancers, particularly prostate (down-regulated zinc transporters ZIP1, 2, 3 and ZnT-2) and breast, notably its high-risk variant (up-regulated ZIP6, 7, 10).
Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells.
Kelleher et al., United States. In Exp Cell Res, 2010
Zip6 over-expression is not an underlying mechanism initiating breast cancer, but in fact may play a "tumor-constraining" role.
Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach.
Zhou et al., Wuhan, China. In Mol Cancer Ther, 2009
The present study identifies LIV1 as a critical mediator responsible for HDACi-induced apoptosis. The effect of LIV1 is, at least in part, mediated by affecting intracellular zinc homeostasis.
Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function.
Hirano et al., Japan. In Nat Immunol, 2006
A zinc chelator mimicked the effects of LPS, whereas zinc supplementation or overexpression of the gene encoding Zip6, a zinc transporter whose expression was reduced by LPS, inhibited LPS-induced upregulation of major histocompatibility complex class II and costimulatory molecules.
Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer.
Hirano et al., Suita, Japan. In Nature, 2004
Here we identify LIV1, a breast-cancer-associated zinc transporter protein, as a downstream target of STAT3 that is essential and sufficient for STAT3's cell-autonomous role in the EMT of zebrafish gastrula organizer cells.
share on facebooktweetadd +1mail to friends